- Home
- MGPI vs TNGX Comparison
MGPI vs TNGX Comparison
Compare MGPI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGPI
- TNGX
- Stock Information
- Founded
- MGPI 1941
- TNGX 2014
- Country
- MGPI United States
- TNGX United States
- Employees
- MGPI N/A
- TNGX N/A
- Industry
- MGPI Beverages (Production/Distribution)
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MGPI Consumer Staples
- TNGX Health Care
- Exchange
- MGPI Nasdaq
- TNGX Nasdaq
- Market Cap
- MGPI N/A
- TNGX 735.0M
- IPO Year
- MGPI 1988
- TNGX N/A
- Fundamental
- Price
- MGPI $57.57
- TNGX $6.64
- Analyst Decision
- MGPI Strong Buy
- TNGX Strong Buy
- Analyst Count
- MGPI 4
- TNGX 8
- Target Price
- MGPI $92.00
- TNGX $15.14
- AVG Volume (30 Days)
- MGPI 386.3K
- TNGX 885.7K
- Earning Date
- MGPI 10-31-2024
- TNGX 11-06-2024
- Dividend Yield
- MGPI 0.83%
- TNGX N/A
- EPS Growth
- MGPI N/A
- TNGX N/A
- EPS
- MGPI 4.33
- TNGX N/A
- Revenue
- MGPI $787,880,000.00
- TNGX $42,509,000.00
- Revenue This Year
- MGPI N/A
- TNGX $18.15
- Revenue Next Year
- MGPI $4.62
- TNGX N/A
- P/E Ratio
- MGPI $13.27
- TNGX N/A
- Revenue Growth
- MGPI N/A
- TNGX 26.16
- 52 Week Low
- MGPI $56.52
- TNGX $6.33
- 52 Week High
- MGPI $102.42
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- MGPI 14.38
- TNGX 37.15
- Support Level
- MGPI $78.93
- TNGX $6.83
- Resistance Level
- MGPI $81.67
- TNGX $7.47
- Average True Range (ATR)
- MGPI 2.58
- TNGX 0.37
- MACD
- MGPI -2.37
- TNGX 0.11
- Stochastic Oscillator
- MGPI 3.02
- TNGX 27.31
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.